HER2-negative, including TNBC or HR-positive for Breast Cancer

"HER2-negative, including TNBC or HR-positive has been used to treat numerous forms of lung cancer. This medication is also frequently employed in the treatment of unresectable melanoma, squamous cell carcinoma, and small cell lung cancer (SCLC)."

"Based on the available evidence, our team at Power estimates that HER2-negative and TNBC or HR-positive has a safety rating of 2. Though there is limited clinical data demonstrating its efficacy, some research points to potential safety outcomes."

"Initially, Spectrum Health Hospital - Butterworth Campus investigated HER2-negative illnesses such as TNBC or HR-positive in 1997. Subsequently, 3474 clinical trials have been completed and 2669 are presently ongoing at medical centres across the nation; a majority of which are located in New york City."

"Presently, 2669 studies focusing on HER2-negative TNBC or HR-positive are being conducted around the world. Across 82 countries and 4442 cities, researchers have been exploring this topic since Alfacell's 1997 trial of 300 subjects which culminated in Phase 3 drug approval. Since then, 3474 trials have concluded their research endeavors."

"This research is not actively seeking participants at this moment. It was first posted on the 2nd of May 2019, and it's most recent update happened on 21st October 2022. If you are looking for additional medical studies, presently there are 2603 trials that target breast cancer patients and 2669 clinical investigations targeting HER2-negative or HR+ individuals who struggle with TNBC recruiting individuals."

"This research trial has expired and is no longer accepting volunteers. It was first posted on May 2nd, 2019 before being updated for the last time in October 21st 2022. If you are seeking alternative studies to join, there are currently 2603 trials recruiting participants with breast cancer and 2669 investigations looking for individuals suffering from HER2-negative including TNBC or HR-positive diseases."